Insider Selling: Verastem (NASDAQ:VSTM) CFO Sells $17,092.02 in Stock

Verastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins sold 4,089 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $4.18, for a total transaction of $17,092.02. Following the completion of the sale, the chief financial officer directly owned 117,238 shares of the company’s stock, valued at $490,054.84. The trade was a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Verastem Stock Performance

Shares of VSTM opened at $3.78 on Friday. The firm’s 50 day moving average is $4.65 and its 200-day moving average is $5.91. The stock has a market capitalization of $332.15 million, a P/E ratio of -1.40 and a beta of 0.27. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.04 and a quick ratio of 3.00. Verastem, Inc. has a 12-month low of $3.43 and a 12-month high of $11.24.

Wall Street Analysts Forecast Growth

VSTM has been the topic of several research reports. Mizuho dropped their price target on Verastem from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Weiss Ratings lowered Verastem from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 17th. Jefferies Financial Group decreased their target price on Verastem from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday. Royal Bank Of Canada restated an “outperform” rating and issued a $15.00 target price on shares of Verastem in a report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Verastem in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $14.60.

Institutional Investors Weigh In On Verastem

Several hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in Verastem by 78.2% in the 1st quarter. AQR Capital Management LLC now owns 62,603 shares of the biopharmaceutical company’s stock worth $377,000 after purchasing an additional 27,477 shares during the period. Goldman Sachs Group Inc. raised its stake in Verastem by 236.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 756,402 shares of the biopharmaceutical company’s stock valued at $4,561,000 after purchasing an additional 531,873 shares during the period. Geode Capital Management LLC raised its stake in Verastem by 24.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,199,259 shares of the biopharmaceutical company’s stock valued at $4,978,000 after purchasing an additional 238,995 shares during the period. Rhumbline Advisers raised its stake in Verastem by 19.2% during the 2nd quarter. Rhumbline Advisers now owns 59,553 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 9,594 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Verastem by 40.0% in the second quarter. Invesco Ltd. now owns 52,063 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 14,879 shares in the last quarter. Hedge funds and other institutional investors own 88.37% of the company’s stock.

Verastem News Summary

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $18 price target on Verastem, reinforcing a bullish long-term view despite lowering near-term earnings estimates.
• Neutral Sentiment: The company continues to draw attention from investors after recent updates on its oncology pipeline, including reported safety and efficacy findings from the RAMP 205 study, which could support longer-term sentiment if development progress continues. InsiderMonkey article on Verastem pipeline update
• Negative Sentiment: HC Wainwright trimmed its earnings outlook across multiple periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2028, FY2029 and FY2030, which signals lower expected profitability than previously modeled.
• Negative Sentiment: Recent insider selling by CEO Dan Paterson and CFO Daniel Calkins may be weighing on sentiment, even though the trades were made under pre-arranged 10b5-1 plans. Insider trade report for Verastem

About Verastem

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.